Development and internal validation of a nomogram for predicting the initial response to radioactive iodine therapy in differentiated thyroid cancer with concurrent Hashimoto's thyroiditis.

IF 1.9 3区 医学 Q3 SURGERY
Gland surgery Pub Date : 2026-08-31 Epub Date: 2026-07-17 DOI:10.21037/gs-2026-0252
Rui Zhu, Yang-Yang Lei, Zhao-Xia Luo, Yi Wu, Ling-Peng Zeng
{"title":"Development and internal validation of a nomogram for predicting the initial response to radioactive iodine therapy in differentiated thyroid cancer with concurrent Hashimoto's thyroiditis.","authors":"Rui Zhu, Yang-Yang Lei, Zhao-Xia Luo, Yi Wu, Ling-Peng Zeng","doi":"10.21037/gs-2026-0252","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Differentiated thyroid cancer (DTC) frequently coexists with Hashimoto's thyroiditis (HT), and HT may influence the response to radioactive iodine (RAI) therapy. This study aims to establish and validate a clinical predictive model for the response to initial RAI therapy in patients with DTC complicated by HT, thereby providing a personalized tool for optimizing clinical decision-making.</p><p><strong>Methods: </strong>A total of 461 patients with DTC and HT were included in the study. Variable selection was conducted using least absolute shrinkage and selection operator (LASSO) regression, followed by the construction of a predictive nomogram based on multivariable binary logistic regression. Model performance was evaluated through receiver operating characteristic (ROC) curve analysis, calibration curve analysis, and decision curve analysis (DCA).</p><p><strong>Results: </strong>Among the 461 patients, 235 achieved an excellent response (ER), while 226 experienced a non-ER (NER). Utilizing five predictors identified by LASSO-N stage, tumor multifocality, lymph node metastasis rate, stimulated thyroglobulin (sTg), and thyroglobulin antibody (TgAb)-a binary logistic regression model and corresponding nomogram were developed. The model demonstrated an area under the ROC curve (AUC) of 0.864 in the training set and 0.882 in the validation set for predicting NER. Moreover, calibration curve analysis and DCA indicated acceptable agreement between predicted and observed outcomes, as well as potential clinical net benefit across a range of threshold probabilities, suggesting that the model may be useful for individualized risk stratification.</p><p><strong>Conclusions: </strong>This study successfully developed and internally validated a clinical prediction model for assessing the response to initial RAI therapy in patients with DTC complicated by HT. The model may serve as a reliable reference for personalized clinical decision-making.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"15 8","pages":"223"},"PeriodicalIF":1.9000,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13561597/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gland surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/gs-2026-0252","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Differentiated thyroid cancer (DTC) frequently coexists with Hashimoto's thyroiditis (HT), and HT may influence the response to radioactive iodine (RAI) therapy. This study aims to establish and validate a clinical predictive model for the response to initial RAI therapy in patients with DTC complicated by HT, thereby providing a personalized tool for optimizing clinical decision-making.

Methods: A total of 461 patients with DTC and HT were included in the study. Variable selection was conducted using least absolute shrinkage and selection operator (LASSO) regression, followed by the construction of a predictive nomogram based on multivariable binary logistic regression. Model performance was evaluated through receiver operating characteristic (ROC) curve analysis, calibration curve analysis, and decision curve analysis (DCA).

Results: Among the 461 patients, 235 achieved an excellent response (ER), while 226 experienced a non-ER (NER). Utilizing five predictors identified by LASSO-N stage, tumor multifocality, lymph node metastasis rate, stimulated thyroglobulin (sTg), and thyroglobulin antibody (TgAb)-a binary logistic regression model and corresponding nomogram were developed. The model demonstrated an area under the ROC curve (AUC) of 0.864 in the training set and 0.882 in the validation set for predicting NER. Moreover, calibration curve analysis and DCA indicated acceptable agreement between predicted and observed outcomes, as well as potential clinical net benefit across a range of threshold probabilities, suggesting that the model may be useful for individualized risk stratification.

Conclusions: This study successfully developed and internally validated a clinical prediction model for assessing the response to initial RAI therapy in patients with DTC complicated by HT. The model may serve as a reliable reference for personalized clinical decision-making.

预测分化型甲状腺癌合并桥本甲状腺炎患者放射碘治疗初期反应的nomogram发展与内部验证。
背景:分化型甲状腺癌(DTC)经常与桥本甲状腺炎(HT)共存,而HT可能影响对放射性碘(RAI)治疗的反应。本研究旨在建立并验证DTC合并HT患者初始RAI治疗反应的临床预测模型,为优化临床决策提供个性化工具。方法:共纳入461例DTC和HT患者。使用最小绝对收缩和选择算子(LASSO)回归进行变量选择,然后基于多变量二元逻辑回归构建预测模态图。通过受试者工作特征(ROC)曲线分析、校准曲线分析和决策曲线分析(DCA)评价模型的性能。结果:461例患者中,235例获得极优缓解(ER), 226例无ER缓解(NER)。利用LASSO-N分期、肿瘤多灶性、淋巴结转移率、促甲状腺球蛋白(sTg)和甲状腺球蛋白抗体(TgAb) 5个预测因子,建立二元logistic回归模型和相应的nomogram。该模型预测NER的训练集和验证集的ROC曲线下面积(AUC)分别为0.864和0.882。此外,校准曲线分析和DCA表明,预测结果和观察结果之间存在可接受的一致性,以及在阈值概率范围内潜在的临床净收益,这表明该模型可能对个体化风险分层有用。结论:本研究成功开发并内部验证了一种临床预测模型,用于评估DTC合并HT患者对初始RAI治疗的反应。该模型可为临床个性化决策提供可靠参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gland surgery
Gland surgery Medicine-Surgery
CiteScore
3.60
自引率
0.00%
发文量
113
期刊介绍: Gland Surgery (Gland Surg; GS, Print ISSN 2227-684X; Online ISSN 2227-8575) being indexed by PubMed/PubMed Central, is an open access, peer-review journal launched at May of 2012, published bio-monthly since February 2015.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书